You are here: Industry Insights > Novartis

News List

Novartis could cut its Kymriah price to $160,000 and keep its profit margins fiercepharma
February 12, 2018
Novartis announced a $475,000 sticker price for Kymriah in August, but a new paper claims the price is three times too high. (Novartis)
BridgeBio Launches QED Therapeutics With $65M and an Abandoned Novartis Cancer Program biospace
January 31, 2018
Palo Alto, Calif.-based BridgeBio Pharma is launching a new spinout to develop a recently-abandoned Novartis cancer treatment now in its possession.
Novartis India appoints Jawed Zia as VC and MD expressbpd
January 30, 2018
At a meeting held in Mumbai today, the Board of Directors of Novartis India announced the appointment of Jawed Zia as VC and MD effective March 1, 2018.
Novartis' Bet Pays Off as Advanced Accelerator Applications Wins FDA Nod for Lutathera biospace
January 29, 2018
Advanced Accelerator Applications, a leader in Novartis and nuclear medicine, announced today that it has received FDA approval for its new drug application
Why This Heart Drug Could Be a $5B Blockbuster for Novartis biospace
January 25, 2018
ZURICH (Reuters) - A Novartis executive said the Swiss company’s heart failure medicine Entresto could be used more widely in future, potentially making it a blockbuster drug with revenue potential of $4 billion to $5 billion a year.
Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in epis worldpharmanews
January 23, 2018
The study met its primary endpoint, with significantly more patients taking erenumab experiencing at least a 50% reduction from baseline in their monthly migraine days as compared to placebo.
Novartis, feeling the heat from head-to-head rivals, pulls Arzerra outside the U.S. fiercepharma
January 23, 2018
The commercial life for Novartis’ Arzerra outside the U.S. is coming to an end.
Novartis' CAR T therapy Kymriah scores accelerated approval in both Europe and US pharmafile
January 18, 2018
Novartis has accepted its proposed label expansion under the accelerated supervision of the two sides of the Atlantic.
Here’s the Chance?! A Core Patent of Novartis’ Entresto in China is Fully Declared Invalid Caicai
January 18, 2018
The festive atmosphere has become increasingly strong as the Chinese New Year is approaching, and there has been good news in the pharmaceutical circle in China...
Novartis’ Cosentyx beats J&J’s Stelara in psoriasis trial pharmatimes
January 17, 2018
Novartis has released trial data showing that Cosentyx was “significantly more effective” than Johnson & Johnson’s rival biologic Stelara in achieving clear skin in patients with psoriasis.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page